Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/8/2025

Cardiovascular Disease Management with Statins

Patient Assessment and Monitoring

  • The European Society of Cardiology recommends measuring liver enzymes (ALT) before starting rosuvastatin treatment, and checking liver enzymes 8-12 weeks after starting treatment or after dose increases, with routine monitoring thereafter not recommended unless clinically indicated 1
  • Before starting therapy, measure baseline creatine kinase (CK) levels, and if baseline CK >4× ULN, do not start therapy; recheck, as recommended by the European Heart Journal 1
  • Monitor for myopathy symptoms, especially in high-risk patients, such as elderly patients, patients on multiple medications, and those with liver or renal disease, as suggested by the European Heart Journal 1
  • If CK ≥4× ULN, follow specific guidelines for treatment continuation or discontinuation, as outlined by the European Heart Journal 1

Dose Selection and Adjustment

  • For patients with severe renal impairment (GFR <30 mL/min/1.73m²), the European Heart Journal and American College of Cardiology recommend a starting dose of 5 mg daily, with a maximum dose of 10 mg daily 1, 2
  • For patients with mild to moderate kidney disease, no dose adjustment is needed 1
  • The following table summarizes the dose adjustments for statins in patients with CKD:
Statin Dose Adjustment
Atorvastatin No adjustment needed for GFR ≥58 mL/min/1.73 m²
Pravastatin No adjustment needed for GFR ≥58 mL/min/1.73 m²
Simvastatin No adjustment needed for GFR ≥58 mL/min/1.73 m²
Fluvastatin No adjustment needed for GFR ≥58 mL/min/1.73 m²
Rosuvastatin No adjustment needed for mild to moderate kidney disease, but dose adjustment necessary when GFR falls below 30 mL/min/1.73 m²
Rosuvastatin (Asian patients) Lower starting dose of 5 mg once daily, compared to 10 mg in non-Asian patients

Contraindications and Precautions

  • Rosuvastatin is contraindicated in patients with acute liver failure and decompensated cirrhosis
  • Patients with substantial alcohol consumption, history of liver disease, or concomitant hepatotoxic medications require careful assessment
  • Concomitant use of rosuvastatin with cyclosporine, gemfibrozil, teriflunomide, enasidenib, or capmatinib requires dose limitation, and concomitant use with dabigatran is contraindicated due to P-gp inhibition 3, 4, 5

Special Populations

  • Asian patients may require lower doses due to increased median exposure, with a recommended starting dose of 5 mg daily, compared to 10 mg in non-Asian patients 2, 1, 4
  • Elderly patients, patients on multiple medications, and those with liver or renal disease are at higher risk for myopathy and require careful monitoring, as suggested by the European Heart Journal 1
  • In hemodialysis patients, rosuvastatin 10 mg may be administered without the need for dose reduction, as the clearance of rosuvastatin via dialysis is minimal, according to findings from the AURORA trial and other research 2, 1
  • Patients with stage 3-5 CKD are considered at high or very high cardiovascular risk, and statin or statin/ezetimibe combination is strongly indicated in patients with non-dialysis-dependent CKD, according to the European Society of Cardiology and Kidney Disease: Improving Global Outcomes guidelines 1, 6, 7, 8

Treatment Considerations

  • Before initiating statin therapy, it is recommended to assess baseline renal function and check for potential drug interactions, and during treatment, monitor for symptoms of myopathy, periodically reassess renal function, and monitor liver function tests, to minimize the risk of adverse effects, as noted by the Kidney Disease: Improving Global Outcomes guidelines 1, 6, 5, 7
  • Discontinuing beneficial statin therapy in non-dialysis CKD patients should be avoided, as statins provide significant cardiovascular protection in this population, according to research published in the European Heart Journal, and the Kidney Disease: Improving Global Outcomes guidelines recommend avoiding high-intensity statins for patients with eGFR <60 mL/min/1.73m², due to increased risk of myopathy 1, 6

REFERENCES

8

Statin Use in Patients with Kidney Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025